Yearly Archives: 2020


Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the closing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share, before underwriting discounts and commissions. All of the shares in the public offering were sold by Arcutis. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arcutis, were $100.0 million. In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Arcutis’ common stock at the public offering price less the underwriting discounts and commissions.

View post:
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1.44 million additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to C4T from the offering were $209.76 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by C4T.

The rest is here:
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created role of NanoFlu™ General Manager. Mr. Wilson will focus exclusively on leading efforts to advance NanoFlu, the company’s influenza vaccine candidate, through global licensure, as well as the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting. Novavax announced results of its successful NanoFlu pivotal Phase 3 clinical trial earlier this year and intends to seek regulatory approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway previously granted to the company.

Continued here:
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate PC14586, for the treatment of cancer patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. There are currently no FDA-approved medicines that target the p53 Y220C mutation.

See more here:
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, October 20, 2020 at 10:00 am ET.

Link:
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

STEM Animal Health Appoints New President and CEO

WINNIPEG, Manitoba, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that Kevin Cole will assume the role of President and CEO of STEM Animal Health Inc. (“STEM”), a subsidiary created from the recently formed joint venture with UK-based international veterinary products company, Animalcare Group PLC (AIM:ANCR) (“Animalcare”).

Read the rest here:
STEM Animal Health Appoints New President and CEO

CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED – The Silicon Valley Voice

In a recent clinical trial for an immune cell therapy for lymphoma, 62% of patients experienced complete cancer clearance in spite of the fact that some of them were on their 5th line of treatment. Stem cell therapies have the potential to enact more of these paradigm-shifting treatments. Proposition 14 will continue to advance these therapies and bring them to full development as available cures.

The vision of stem cell therapy is that a physician can just as easily grab an IV bag full of therapeutic cells as they might draw a drug into a syringe. Conceived through Proposition 71 in 2004, the California Institute for Regenerative Medicine (CIRM) serves as a vehicle to support all aspects of stem cell research. Medical progress requires not just well-designed clinical studies but also a well-trained workforce, educated at the intersection of stem cell biology, engineering, and chemistry.

Since 2008, CIRM has supported the training of nearly 1300 Community College and California State University students for the emerging field of Regenerative Medicine through the Bridges to Stem Cell Research and Therapy Program. The Bridges Training Program has functioned as a pathway for first-generation and underrepresented students from Humboldt to San Diego, to all of the biomedical sectors startup and cell therapy companies, academic research institutes, graduate and medical school, and more. Exposure to hands-on labs, advanced seminar discussions, and a required paid internship fully prepares these students for entering the stem cell workforce. Over 80% of Bridges alumni have either advanced to graduate school or joined the biomedical workforce in industry or academic institutions. These Programs bring a greater return than the initial cost of training.

SPONSORED

Consider Vahid Hamzeinejad, a bright high school student, headed to UC Berkeley to begin his college career. Enter the Great Recession; Vahid found himself back at home, working non-stop to help keep his parents restaurant afloat. Not giving up on his commitment to an education, he enrolled at the College of the Canyons. After completing an Associates degree, Vahid transferred to Cal Poly, hoping to join the Bridges Program. After receiving the Bridges core training, Vahid started his internship at ViaCyte, where he continues to work today, as a critical member of the team supporting ViaCytes clinical development of a functional cure for diabetes. The nearly $30 billion that California currently spends on diabetes treatments could be significantly reduced, in no small part due to the efforts of a student that cost taxpayers $36,000 to educate. That is before considering the benefit to patients quality of life that would occur by replacing insulin pumps, glucose monitors, and constant vigilance with a stem-cell-derived tissue that regulates blood sugar levels biologically making and secreting its own insulin.

Passing Proposition 14 will enable this and other unparalleled treatments for diabetes, heart disease, cancer, and neurological disorders.

Signed,

Robert Kam and the CIRM Bridges Program

SPONSORED

Read more:
CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED - The Silicon Valley Voice

COVID-19 and the trials of treatment | News, Sports, Jobs – Escanaba Daily Press

Features

Oct 16, 2020

Karen Wils photo Shown at right is Karen Wils, the Chemo Beagler or the COVID Beagler.

ESCANABA The year 2020 has put me and most everybody else in a very unusual position.

We all feel a little trapped and uneasy thrown into a situation we have never faced before.

I always kind of thought I would need to have a stem cell transplant someday after I was diagnosed with multiple myeloma in 2008.

I often referred to this blood cancer as my pesky woodtick. Fortunately, I have been blessed with good control of the disease until this year.

Leaving home, going to the Mayo Clinic and going through transplant is enough excitement for one person, but to be doing that while COVID-19 plagues our country is almost too much.

To say the last few months have been an interesting journey would be putting it mildly.

As the summer drew to a close, many changes were closing in on me, too. My son went off to a new job, and my daughter left for college. The very next week, my husband and I left for Minnesota for an unknown amount of weeks for my stem cell transplant.

For three-and-a-half weeks we were at Mayo. My husband was my excellent care giver through the strong chemo, and the transplant of my own stem cells and the long road to recovery.

Doing all of this during a pandemic is really interesting. The Mayo Clinic takes COVID-19 very seriously. So with much testing, temperature taking, sanitizing and constant mask wearing, we maneuvered through the treatment.

Social distancing when you are staying at the Gift of Life Transplant House and so far from home is very difficult. Phone calls, Zoom and Facebook became my life link to the kids, family and friends.

After going through some pretty weak days, finally my new immune system was strong enough for me to go home.

Oh, the great joy of heading down those last miles from Menominee to Escanaba back into the land of trees and water!

Sleeping in my own bed, seeing my pets, and being able to stand in my own garden felt so wonderful, but the house was so quiet without the kids.

The COVID-19 cautions had to continue, too.

I wear my mask and feel a little bit trapped, like everybody else these days. I pray that I am making all healthy decisions when I encourage my children to go to church or my husband to go to the grocery store.

The COVID-19 virus threatens big things and little things like family traditions that have to be rethought. With great sadness, I postponed until next year our annual camp gathering/harvest festival. So many folks have been through canceled or postponed parties, birthdays, anniversaries and funerals.

As hard and as disappointing as this is, the important things remain. The trees still are changing to awesome autumn colors. The harvest season is in full swing. The wild animals are still thriving outside our windows, and our families are together even if we cant do everything we want to do right now.

As I get stronger every day, I thank God. I pray for a cure for COVID-19. Yoopers are tough and our traditions will thrive long after this pandemic!

Karen (Rose) Wils is a lifelong north Escanaba resident. Her folksy columns appear weekly in Lifestyles.

Today's breaking news and more in your inbox

Dear Heloise: When my daughter was getting married, I gave her a number of bulky items for her shower, including ...

Dear Annie: After years of fiscal discipline, my wife and I have paid off our mortgage. We contemplated having a ...

(Family Features) For some, the holidays may be the happiest season of all, but for others the hectic pace and ...

Last Isabella farmers market is today ISABELLA The Isabella Community Hall will hold its last farmers ...

Annual Right to Life poster contest ESCANABA Right to Life of Delta County will hold its seventh annual ...

See the rest here:
COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press